Table 1.
Baseline demographic and clinical characteristics of the study population.
| Clinical characteristic | Entire cohort (n=19) |
Ischemic subgroup | ||
|---|---|---|---|---|
| CAD− / Lactate elution− (n=5) |
CAD+/ Lactate elution− (n=7) |
CAD+/ Lactate elution+ (n=7) |
||
| Age (years) | 52±6 | 49±2 | 52±8 | 54±6 |
| Gender (no., % female) | 7 (37) | 4 (80) | 0 (0) | 3 (43) |
| Race/ethnicity | ||||
| White | 6 (32) | 2 (40) | 3 (43) | 1 (14) |
| Black | 8 (42) | 3 (60) | 2 (29) | 3 (43) |
| Hispanic | 5 (26) | 0 (0) | 2 (29) | 3 (43) |
| Hypertension (%) | 14 (74) | 5 (100) | 5 (71) | 4 (57) |
| Hyperlipidemia (%) | 13 (68) | 2 (40) | 6 (86) | 5 (71) |
| Diabetes mellitus (%) | 8 (42) | 0 (0) | 4 (57) | 4 (57) |
| Tobacco use (%) | 11 (58) | 3 (60) | 4 (57) | 4 (57) |
| Canadian Cardiovascular Society Angina Score | ||||
| I | 2 (11) | 1 (20) | 0 (0) | 1 (14) |
| II | 9 (47) | 1 (20) | 6 (86) | 2 (29) |
| III | 8 (42) | 3 (60) | 1 (14) | 4 (57) |
| LVEF [%, median (25th,75th)] | 53 (42,59) | 55 (45,55) | 50 (45,63) | 51 (38,63) |
| Creatinine [mg/dl, median (25th,75th)] | 1.0 (0.8,1.3) | 0.9 (0.8,1.2) | 0.9 (0.8,1.1) | 1.3 (0.8,1.8) |
| Chronic medications | ||||
| ACE-inhibitor/ARB | 12 (63) | 2 (40) | 4 (57) | 6 (86) |
| β-blocker* | 16 (84) | 4 (80) | 6 (86) | 6 (86) |
| Statin | 11 (58) | 1 (20) | 5 (71) | 5 (71) |
*
held for ≥24hrs prior to procedure